ASCO 2014：放射性碘治疗无效的晚期分化型甲状腺癌的Ⅲ期研究

2014-06-04 CMT肿瘤中国医学论坛报

第50届美国临床肿瘤学会年会(ASCO2014)正在美国芝加哥召开。芝加哥——当地时间5月31日新闻发布会的重头戏是针对常见、难治性癌症的4项新型靶向药物的临床研究。据ASCO">ASCO新闻稿报道，这4项在研药物的临床研究分别针对晚期卵巢癌、肺癌、慢性淋巴细胞白血病(CLL)和甲状腺癌，均获得了阳性结果，提示能延缓疾病进展并且能使复发或者对当前治疗耐药患者的生存得以改善。

第50届美国临床肿瘤学会年会(ASCO2014)正在美国芝加哥召开。芝加哥——当地时间5月31日新闻发布会的重头戏是针对常见、难治性癌症的4项新型靶向药物的临床研究。据ASCO">ASCO新闻稿报道，这4项在研药物的临床研究分别针对晚期卵巢癌、肺癌、慢性淋巴细胞白血病(CLL)和甲状腺癌，均获得了阳性结果，提示能延缓疾病进展并且能使复发或者对当前治疗耐药患者的生存得以改善。

其中有1项是将在当地时间6月2日头颈部癌症口头摘要专场(10:28)报告的SELECT研究，是关于放射性碘治疗无效的晚期分化型甲状腺癌的一项Ⅲ期研究，纳入392例1年内出现进展的患者，随机接受新型口服靶向药物酪氨酸激酶抑制剂lenvatinib或安慰剂治疗。结果提示，lenvatinib对于此类患者非常有效，延缓疾病进展达14.7个月，并且几乎2/3的患者表现肿瘤缩小，但中位总生存还未达到;最常见的5种不良反应为高血压、腹泻、食欲下降、体重减轻和恶心，并且其疗效未受到因不良反应而减量的影响。

主要研究者、来自法国巴黎的Martin Schlumberger教授表示，就在1年前，这组患者还无有效的治疗选择，基于我们的发现，lenvatinib将最终成为放射性碘治疗无效甲状腺癌患者的一种标准治疗。

新闻发布会主持人、ASCO专家Gregory A.Masters评论，分化型甲状腺癌进展时，患者的治疗选择非常有限，在患者病情恶化前，lenvatinib有助延长患者生存，其不良反应可以控制，是一种有效治疗选择。

(本文摘译自ASCO官方新闻稿)

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1651277, encodeId=cd6816512e7cd, content=<a href='/topic/show?id=2de45e3662c' target=_blank style='color:#2F92EE;'>#放射性碘治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57366, encryptionId=2de45e3662c, topicName=放射性碘治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29d724152261, createdName=redcrab, createdTime=Thu Oct 09 02:56:00 CST 2014, time=2014-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938391, encodeId=728119383914c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Oct 14 07:56:00 CST 2014, time=2014-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322566, encodeId=61f313225664d, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Fri Jun 06 00:56:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395421, encodeId=259d139542132, content=<a href='/topic/show?id=504f5e36317' target=_blank style='color:#2F92EE;'>#放射性碘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57363, encryptionId=504f5e36317, topicName=放射性碘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 06 00:56:00 CST 2014, time=2014-06-06, status=1, ipAttribution=)]
2014-10-09 redcrab

#放射性碘治疗#

75 0
[GetPortalCommentsPageByObjectIdResponse(id=1651277, encodeId=cd6816512e7cd, content=<a href='/topic/show?id=2de45e3662c' target=_blank style='color:#2F92EE;'>#放射性碘治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57366, encryptionId=2de45e3662c, topicName=放射性碘治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29d724152261, createdName=redcrab, createdTime=Thu Oct 09 02:56:00 CST 2014, time=2014-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938391, encodeId=728119383914c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Oct 14 07:56:00 CST 2014, time=2014-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322566, encodeId=61f313225664d, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Fri Jun 06 00:56:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395421, encodeId=259d139542132, content=<a href='/topic/show?id=504f5e36317' target=_blank style='color:#2F92EE;'>#放射性碘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57363, encryptionId=504f5e36317, topicName=放射性碘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 06 00:56:00 CST 2014, time=2014-06-06, status=1, ipAttribution=)]
2014-10-14 quxin068

#ASC#

65 0
[GetPortalCommentsPageByObjectIdResponse(id=1651277, encodeId=cd6816512e7cd, content=<a href='/topic/show?id=2de45e3662c' target=_blank style='color:#2F92EE;'>#放射性碘治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57366, encryptionId=2de45e3662c, topicName=放射性碘治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29d724152261, createdName=redcrab, createdTime=Thu Oct 09 02:56:00 CST 2014, time=2014-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938391, encodeId=728119383914c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Oct 14 07:56:00 CST 2014, time=2014-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322566, encodeId=61f313225664d, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Fri Jun 06 00:56:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395421, encodeId=259d139542132, content=<a href='/topic/show?id=504f5e36317' target=_blank style='color:#2F92EE;'>#放射性碘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57363, encryptionId=504f5e36317, topicName=放射性碘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 06 00:56:00 CST 2014, time=2014-06-06, status=1, ipAttribution=)]
2014-06-06 dzx0922889

#分化型甲状腺癌#

72 0
[GetPortalCommentsPageByObjectIdResponse(id=1651277, encodeId=cd6816512e7cd, content=<a href='/topic/show?id=2de45e3662c' target=_blank style='color:#2F92EE;'>#放射性碘治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57366, encryptionId=2de45e3662c, topicName=放射性碘治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29d724152261, createdName=redcrab, createdTime=Thu Oct 09 02:56:00 CST 2014, time=2014-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938391, encodeId=728119383914c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Oct 14 07:56:00 CST 2014, time=2014-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322566, encodeId=61f313225664d, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Fri Jun 06 00:56:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395421, encodeId=259d139542132, content=<a href='/topic/show?id=504f5e36317' target=_blank style='color:#2F92EE;'>#放射性碘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57363, encryptionId=504f5e36317, topicName=放射性碘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 06 00:56:00 CST 2014, time=2014-06-06, status=1, ipAttribution=)]
2014-06-06 仁医06

#放射性碘#

78 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

ASCO 2014：放射性碘治疗无效的晚期分化型甲状腺癌的Ⅲ期研究

相关资讯

科室

工具

服务